Evidence‐based prescribing of drugs for secondary prevention of acute coronary syndrome in Aboriginal and non‐Aboriginal patients admitted to Western Australian hospitals
- 23 April 2014
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 44 (4) , 353-361
Abstract
Aims: To assess the level of evidence‐based drug prescribing for acute coronary syndrome (ACS) at discharge from Western Australian (WA) hospitals and determine predictors of such prescribing in Aboriginal and non‐Aboriginal patients.Methods: All Aboriginal (2002–2004) and a random sample of non‐Aboriginal (2003) hospital admissions with a principal diagnosis of ACS were extracted from the WA Hospital Morbidity Data Collection of WA Data Linkage System. Clinical information, history of co‐morbidities and drugs were collected from medical notes by trained data collectors. Evidence‐based prescribing (EBP) was defined as prescribing of aspirin, statin and beta‐blocker or angiotensin‐converting enzyme inhibitor/angiotensin II antagonist.Results: Records for 1717 ACS patients discharged alive from hospitals were reviewed. The majority of patients (71%) had EBP, and there was no significant difference between Aboriginal and non‐Aboriginal patients (70% vs 71%, P = 0.36). Conversely, a significantly higher proportion of Aboriginal patients had none of the drugs prescribed compared with non‐Aboriginal patients (11% vs 7%, P < 0.01). EBP for ACS was independently associated with male sex (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.26−2.11), previous admission for ACS (OR 1.83, 95% CI 1.39–2.42) and diabetes (OR 1.36, 95% CI 1.04–1.79). However, ACS patients living in regional and remote areas, attending district or private hospitals, or with a history of chronic obstructive pulmonary disease were significantly less likely to have ACS drugs prescribed at discharge.Conclusions: Opportunity exists to improve prescribing of recommended drugs for ACS patients at discharge from WA hospitals in both Aboriginal and non‐Aboriginal patients. Attention regarding pharmaceutical management post‐ACS is particularly required for patients from rural and remote areas, and those attending district and private hospitals.Keywords
Funding Information
- National Health and Medical Research Council of Australia (1031057)
- NHMRC early career fellowship (037429)
- Department of Health and Ageing
This publication has 31 references indexed in Scilit:
- Medication Use Pattern and Predictors of Optimal Therapy at Discharge in 8176 Patients With Acute Coronary Syndrome From 6 Middle Eastern Countries: Data From the Gulf Registry of Acute Coronary EventsAngiology, 2011
- Physician and Patient Influences on Provider PerformanceCirculation: Cardiovascular Quality and Outcomes, 2011
- Incidence of and Case Fatality Following Acute Myocardial Infarction in Aboriginal and Non-Aboriginal Western Australians (2000–2004): A Linked Data StudyHeart, Lung and Circulation, 2010
- Can patients with COPD or asthma take a beta-blockerCleveland Clinic Journal of Medicine, 2010
- Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromesHeart, 2009
- Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practiceJournal of Clinical Pharmacy and Therapeutics, 2008
- Current management of acute coronary syndromes in Australia: observations from the acute coronary syndromes prospective auditInternal Medicine Journal, 2007
- Effect of drug combinations on admission for recurrent myocardial infarctionHeart, 2007
- Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000Circulation, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987